Ziltivekimab's failure in a key trial spurred share sell-offs for Novo and other biotechs, as it suggested trouble for different cardiovascular drugs that also target inflammation.
An article from
Dive Brief
Ziltivekimab’s failure in a key trial hurt the stocks of Novo and multiple other biotechs, as it suggested trouble for different cardiovascular drugs that also target inflammation.
Published July 31, 2026
Novo Nordisk's ziltivekimab failed to meaningfully reduce the risk of heart attacks, strokes and cardiovascular death in a Phase 3 trial.
Novo Nordisk shares dive 9% after heart medicine fails trial
Novo Nordisk Says Anti-Inflammatory Drug Trial Fails to Cut Cardiovascular Risk in High Risk Patients - N
Is Novo Nordisk Stock (NVO) a Good Buy After Today’s Plunge?
Novo Nordisk: Wirkstoff Ziltivekimab ist ein Entwicklungs-Fehlschlag
Novo Nordisk rocked by late-stage cardiovascular drug failure
Pharma: Novo Nordisk mit Entwicklungsfehlschlag – Aktienkurs sackt ab
Novo Nordisk inflammation-targeting drug misses mark in heart disease study
Novo Nordisk’s Market Value Sheds $30 Billion—Here’s Why Shares Are Down
Novo-aktien tager stort dyk efter studie med skidt nyt
Why Is BioAge Labs Stock Sinking Friday? - Neumora Therapeutics (NASDAQ:NMRA), Bioage Labs (NASDAQ:BIOA)
The experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse…
Novo Nordisk Phase 3 ZEUS trial shows ziltivekimab missed MACE risk reduction. Operating profit outlook unchanged despite Q3…
Novo Nordisk (NVO) shares dropped about 9% today after the company reported that its experimental heart drug ziltivekimab failed…
Ein Wirkstoff von Novo Nordisk für das Herz-Kreislaufsystem schneidet offenbar nicht so ab, wie gewünscht – und lässt den…
An anti-inflammatory drug from Novo Nordisk unexpectedly failed in a Phase 3 study that aimed to prove a link between…
Der dänische Pharmariese scheitert mit seinem Herzmittel Ziltivekimab in einer zulassungsrelevanten Studie. Es hätte ein…
